Early recognition of CKD can delay progression

Area of Science:

• Nephrology
• Public Health

Background:

• Chronic kidney disease (CKD) affects 8.5% of the UK population, defined by reduced estimated glomerular filtration rate (eGFR) or kidney damage.
• Early recognition of CKD enables interventions to slow progression and manage associated cardiovascular risks.
• CKD is staged 1-5, with most cases being stages 1-3, often not progressing to end-stage renal disease.

Purpose of the Study:

• To outline the definition, prevalence, classification, and initial assessment of Chronic Kidney Disease (CKD).
• To highlight key prognostic markers and associated health problems in CKD patients.
• To emphasize the importance of early detection and management of CKD.

Main Methods:

• Definition of CKD based on eGFR reduction or kidney damage.
• Classification of CKD into five stages.
• Recommended baseline assessments including blood pressure, urinalysis (ACR/PCR), glucose, lipids, and full blood count.

Main Results:

• Common causes of progressive CKD in the UK include diabetes, renal vascular disease, glomerulonephritis, pyelonephritis, and inherited diseases.
• Laboratories routinely provide eGFR estimations based on serum creatinine, age, gender, and ethnicity.
• Proteinuria, particularly measured by ACR, is a critical prognostic marker.

Conclusions:

• CKD management requires comprehensive baseline assessment and monitoring.
• Proteinuria assessment is vital for prognosis in CKD.
• CKD is associated with risks of renal bone disease, anemia, and significant cardiovascular disease.